If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

 

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,773.50
Bid: 1,772.00
Ask: 1,772.50
Change: 12.50 (0.71%)
Spread: 0.50 (0.028%)
Open: 1,770.00
High: 1,776.00
Low: 1,766.00
Prev. Close: 1,761.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: UK Stocks To Open Higher Ahead Of BoE Minutes

Wed, 22nd Oct 2014 06:35

LONDON (Alliance News) - UK stocks are set to open higher Wednesday, following gains made in the US and Asia and ahead of the release of the minutes from the October meeting of the Monetary Policy Committee of the Bank of England.

Futures indicate the FTSE 100 will open 20 points higher at 6,392.

The UK's leading index, along with other major European indices, made significant gains on Tuesday amid reports that the European Central Bank is looking to take further steps to boost the slowing eurozone economy. Reuters reported that the ECB is considering buying bonds in the secondary market as part of its effort to boost lending in the single currency block. The central bank could take a decision as soon as December, Reuters said.

"The fact that story pushed equities up should be further evidence that it is central banks, not fundamentals, driving market momentum at the moment," says Rabobank analyst Michael Every.

Equity markets have seen a significant increase in volatility recently as investors show their nervousness over whether the global economy is strong enough to stand on its own two feet, without the extra support of the US quantitative easing programme that ends this month.

Hope of further stimulus was enough to help US investors look past mixed earnings and push Wall Street higher. The DJIA gained 1.3% higher, the S&P 500 2.0%, and the Nasdaq Composite 2.4%.

US Technology bellwether Yahoo Inc beat estimates on Tuesday by reporting third quarter earnings per share of USD0.52, much better than the USD0.30 that had been forecast by analysts. The profit includes a 6.3-billion-dollar gain from Yahoo's sale of a stake in the Alibaba Group, as part of the Chinese company's initial public offering in September.

Not all US earnings were so positive however, with McDonald's Corp, for example, reporting earnings per share of USD1.09 in the third quarter, down from USD1.52 last year and missing expectations for USD1.37.

It has been a positive Asian session so far Wednesday, with the Nikkei closing up about 2.5%, while the Hang Seng continues up 1.4%, and the Shanghai Composite is fractionally higher.

The domestic economic focus in the UK Wednesday is the release of the minutes from the latest MPC meeting at the Bank of England. The committee elected to keep the UK base rate on hold at a record low of 0.5% at the meeting earlier this month, but given that two of its members voted for a rate rise in September, investors will be keen to see how the vote was split this month. Given the recent market volatility, calls for rate rises have been somewhat subdued and the consensus expectation is for an unchanged 7-2 vote to keep rates on hold.

One of BoE's most notable hawks, Martin Weale, will be speaking after the market close at 2000 BST in Cambridge. Weale and Ian McCafferty were the two Monetary Policy Committee members to vote for a rate rise last month.

From the UK corporate calendar Wednesday, British American Tobacco has joined the list of names highlighting the impact of the strength of the pound on its earnings. The cigarette maker said its nine-month revenue was up 2.4% at constant exchange rates but down 9.6% at actual rates.

Updates are also out Wednesday from Playtech, International Personal Finance, and Spirit Pub Co. GlaxoSmithKline is reporting third-quarter earnings at 1200 BST.

In the afternoon, the attention will shift to the US where third quarter earnings season continues with a multitude of names including AT&T Inc and Boeing Company reporting.

US consumer price inflation at 1330 BST will be of key interest given the heightened concerns over the strength of the economy as stimulus is withdrawn. The expectation is for a slight fall in CPI to 1.6% year-on-year in September, from 1.7% in August. The US, like the UK, targets 2.0% inflation, and anything greater than the expected 0.1% fall will likely cause some concern, analysts say.

By Jon Darby; jondarby@alliancenews.com; @jondarby100

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.